Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $1.1 billion.

  • Beam Therapeutics' Liabilities and Shareholders Equity rose 11.93% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 0.40%. This contributed to the annual value of $1.1 billion for FY2024, which is 24.38% down from last year.
  • Per Beam Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $1.1 billion for FY2024, which was down 24.38% from $1.5 billion recorded in FY2023.
  • Beam Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $1.5 billion for FY2021, and its period low was $451.7 million during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.3 billion (2022), whereas its average is $1.3 billion.
  • Per our database at Business Quant, Beam Therapeutics' Liabilities and Shareholders Equity soared by 226.44% in 2021 and then dropped by 24.38% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Liabilities and Shareholders Equity stood at $451.7 million in 2020, then skyrocketed by 226.44% to $1.5 billion in 2021, then decreased by 9.00% to $1.3 billion in 2022, then increased by 8.79% to $1.5 billion in 2023, then fell by 24.38% to $1.1 billion in 2024.